half-dose ticagrelor — Competitive Intelligence Brief

half-dose ticagrelor (half-dose ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist. Area: Cardiovascular.

marketed P2Y12 receptor antagonist P2Y12 Cardiovascular Small molecule

Target snapshot

half-dose ticagrelor (half-dose ticagrelor) — First Affiliated Hospital of Harbin Medical University. Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
half-dose ticagrelor TARGET	half-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	marketed	P2Y12 receptor antagonist	P2Y12
Ticlid	TICLOPIDINE		marketed	ADP receptor antagonist	P2Y12	1991-01-01
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
Ticagrelor + ASA + Bivalirudin	Ticagrelor + ASA + Bivalirudin	Juan J Badimon	marketed	Antiplatelet agent + anticoagulant combination	P2Y12 receptor, COX-1, thrombin
Edoxaban plus Single Antiplatelet Agent	Edoxaban plus Single Antiplatelet Agent	Gi-Byoung Nam	marketed	Factor Xa inhibitor + antiplatelet agent combination	Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent)
standard-dose ticagrelor	standard-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	marketed	P2Y12 receptor antagonist	P2Y12

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist class)

1. First Affiliated Hospital of Harbin Medical University · 4 drugs in this class
2. Fu Wai Hospital, Beijing, China · 1 drug in this class
3. Ping-Yen Liu · 1 drug in this class
4. Samsung Medical Center · 1 drug in this class
5. St. Antonius Hospital · 1 drug in this class
6. University of Florida · 1 drug in this class